Joe Nabhan
Chief Scientific Officer K2B Therapeutics
Joe Nabhan, Ph.D., is a seasoned scientific leader with over a decade of experience driving innovation in oncology and rare disease drug discovery. He currently serves as the Chief Scientific Officer at K2B Therapeutics, developing next-generation protein drug conjugates for cancer. Previously, he was CSO at Vesigen Therapeutics and held roles of increasing responsibility at Astellas Pharma and Pfizer. Dr. Nabhan has a proven track record of leading cross-functional teams, managing diverse preclinical programs, and forging strategic collaborations.
Seminars
- Featuring a proprietary tumor-directed protein, which mediates potent and selective biodistribution to tumors, as validated by higher payload concentration
- Demonstrating efficient functional delivery in vitro and in vivo of siRNA molecules to cancer cells for therapeutic application, achieving robust oncogene silencing and a profound anti-tumor effect
- Exploring the utility of siRNA delivery as an adjunct therapy to drug conjugates to sequentially disrupt oncogenic pathways and eradicate tumor cells, thereby overcoming mechanism-based resistance
The therapeutic window of RNAi is defined by the intricate balance between potent silencing and off-target effects, driven by advances in chemical modifications, novel conjugate strategies, and a deeper understanding of RNAi pharmacology. This roundtable convenes experts pioneering these chemical and biological innovations to define the principles for building better, safer RNAi therapeutics by discussing:
- How are novel phosphorothioate patterns, 2’-modifications, and scaffold designs being used to actively direct biodistribution, improve cellular uptake, and facilitate endosomal escape
- Comparing the advantages, limitations, and unique pharmacological profiles of emerging delivery vehicles.
- Integrating predictive tools for immunogenicity and off-target effects early in candidate selection.
